PMID- 37143440 OWN - NLM STAT- MEDLINE DCOM- 20230804 LR - 20230809 IS - 2056-4538 (Electronic) IS - 2056-4538 (Linking) VI - 9 IP - 5 DP - 2023 Sep TI - NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS. PG - 367-377 LID - 10.1002/cjp2.324 [doi] AB - Triple-negative breast cancer (TNBC) is usually an aggressive disease with a poor prognosis and limited treatment options. The neurotrophic tyrosine receptor kinase (NTRK) gene fusions are cancer type-agnostic emerging biomarkers approved by the Food and Drug Administration (FDA), USA, for the selection of patients for targeted therapy. The main aim of our study was to investigate the frequency of NTRK aberrations, i.e. fusions, gene copy number gain, and amplification, in a series of TNBC using different methods. A total of 83 TNBCs were analyzed using pan-TRK immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), real-time polymerase chain reaction (RT-PCR), and RNA-based next-generation sequencing (NGS). Of 83 cases, 16 showed pan-TRK positivity although no cases had NTRK-fusions. Indeed, FISH showed four cases carrying an atypical NTRK1 pattern consisting of one fusion signal and one/more single green signals, but all cases were negative for fusion by NGS and RT-PCR testing. In addition, FISH analysis showed six cases with NTRK1 amplification, one case with NTRK2 copy number gain, and five cases with NTRK3 copy number gain, all negative for pan-TRK IHC. Our data demonstrate that IHC has a high false-positive rate for the detection of fusions and molecular testing is mandatory; there is no need to perform additional molecular tests in cases negativity for NTRK by IHC. In conclusion, the NTRK genes are not involved in fusions in TNBC, but both copy number gain and amplification are frequent events, suggesting a possible predictive role for other NTRK aberrations. CI - (c) 2023 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. FAU - Zito Marino, Federica AU - Zito Marino F AD - Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Naples, Italy. FAU - Buono, Simona AU - Buono S AD - Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Naples, Italy. FAU - Montella, Marco AU - Montella M AD - Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Naples, Italy. FAU - Giannatiempo, Rosa AU - Giannatiempo R AD - Ospedale Evangelico Betania, Naples, Italy. FAU - Messina, Francesco AU - Messina F AD - Ospedale Evangelico Betania, Naples, Italy. FAU - Casaretta, Giovanni AU - Casaretta G AD - Ospedale Evangelico Betania, Naples, Italy. FAU - Arpino, Grazia AU - Arpino G AD - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Vita, Giulia AU - Vita G AD - Anatomical Pathology Department, IRCCS CROB, Rionero in Vulture, Italy. FAU - Fiorentino, Francesco AU - Fiorentino F AD - Pathology Unit, S.M. delle Grazie Hospital, Naples, Italy. FAU - Insabato, Luigi AU - Insabato L AD - Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy. FAU - Sgambato, Alessandro AU - Sgambato A AD - Scientific Direction, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture, Italy. FAU - Orditura, Michele AU - Orditura M AD - Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania "L. Vanvitelli", Naples, Italy. FAU - Franco, Renato AU - Franco R AD - Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Naples, Italy. FAU - Accardo, Marina AU - Accardo M AD - Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Naples, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230504 PL - England TA - J Pathol Clin Res JT - The journal of pathology. Clinical research JID - 101658534 RN - EC 2.7.10.1 (Receptor, trkA) SB - IM MH - Humans MH - *Receptor, trkA/genetics MH - *Triple Negative Breast Neoplasms/genetics MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Reverse Transcriptase Polymerase Chain Reaction MH - High-Throughput Nucleotide Sequencing PMC - PMC10397374 OTO - NOTNLM OT - FISH OT - IHC OT - NGS OT - NTRK amplification OT - NTRK fusions OT - RT-PCR OT - neurotrophic tyrosine receptor kinase (NTRK) OT - triple-negative breast carcinoma EDAT- 2023/05/05 06:42 MHDA- 2023/08/04 06:43 PMCR- 2023/05/04 CRDT- 2023/05/05 03:44 PHST- 2023/03/31 00:00 [revised] PHST- 2022/11/25 00:00 [received] PHST- 2023/04/07 00:00 [accepted] PHST- 2023/08/04 06:43 [medline] PHST- 2023/05/05 06:42 [pubmed] PHST- 2023/05/05 03:44 [entrez] PHST- 2023/05/04 00:00 [pmc-release] AID - CJP2324 [pii] AID - 10.1002/cjp2.324 [doi] PST - ppublish SO - J Pathol Clin Res. 2023 Sep;9(5):367-377. doi: 10.1002/cjp2.324. Epub 2023 May 4.